These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 754480)

  • 21. [Study of the inotropic effect of potassium-canrenoate by systolic time intervals technique (author's transl)].
    Vitolo E; Larovere MT; Gambini E; Rusconi F; Vitali GM
    G Ital Cardiol; 1980; 10(10):1360-5. PubMed ID: 7239083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocardial noradrenaline uptake after coronary occlusion in the rat.
    Préda I; Kárpáti P; Endröczi E
    Acta Physiol Acad Sci Hung; 1975; 46(2):99-106. PubMed ID: 14478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antioestrogenic action of the aldosterone antagonist canrenoate K in the rat (adenohypophysis, ceruloplasmin).
    Schreiber V; Pribyl T
    Physiol Bohemoslov; 1977; 26(5):385-95. PubMed ID: 144921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of furosemide, potassium canrenoate and D-L-propranolol on blood pressure in spontaneously hypertensive rat].
    Altman J; Gordan P; Grünfeld JP
    Pathol Biol (Paris); 1976 May; 24(5):337-41. PubMed ID: 781602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.
    Francavilla A; Di Leo A; Eagon PK; Polimeno L; Guglielmi F; Fanizza G; Barone M; Starzl TE
    Gastroenterology; 1987 Oct; 93(4):681-6. PubMed ID: 3623016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of a spirolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium.
    Coraboeuf E; Deroubaix E
    J Pharmacol Exp Ther; 1974 Oct; 191(1):128-38. PubMed ID: 4418463
    [No Abstract]   [Full Text] [Related]  

  • 28. Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
    Rochetaing A; Chapon C; Marescaux L; Le Bouil A; Furber A; Kreher P
    Can J Physiol Pharmacol; 2003 Sep; 81(9):864-72. PubMed ID: 14614522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism and metabolic disposition of verapamil-evoked overflow of radioactivity from isolated atria preloaded with [3H]norepinephrine.
    Chaudhry A; Vohra MM
    J Pharmacol Exp Ther; 1985 Mar; 232(3):850-6. PubMed ID: 3973833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial uptake of thallous ion in animals.
    Rinck PA; Beckmann HO
    Rofo; 1982 Jun; 136(6):679-80. PubMed ID: 6213495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Action of spironolactone and potassium canrenoate].
    Zaun H
    Hautarzt; 1990 Dec; 41(12):700. PubMed ID: 2089031
    [No Abstract]   [Full Text] [Related]  

  • 32. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of pancuronium on myocardial contraction and catecholamine metabolism.
    Ivankovich AD; Miletich DJ; Albrecht RF; Zahed B
    J Pharm Pharmacol; 1975 Nov; 27(11):837-41. PubMed ID: 1492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of intravenous canrenoate on the determination of digoxin in serum by radio- and enzyme-immunoassay.
    Lichey J; Rietbrock N; Borner K
    Int J Clin Pharmacol Biopharm; 1979 Feb; 17(2):61-3. PubMed ID: 370036
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of fluphenazine on tissue noradrenaline concentrations and its interaction with pargyline.
    Azhary RA; Khayyal MT; Saleh S
    Br J Pharmacol; 1975 Apr; 53(4):593-5. PubMed ID: 1148501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
    Bie P
    Acta Physiol Scand; 1976 Oct; 98(2):272-4. PubMed ID: 983738
    [No Abstract]   [Full Text] [Related]  

  • 38. [Cardiac and selective vascular effects of canrenoate-potassium (aldactone pro injectione) in cardiosurgical patients (author's transl)].
    Piepenbrock S; Hempelmann G; Volkholz E; Oelert H
    Prakt Anaesth; 1977 Oct; 12(5):400-12. PubMed ID: 917981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-induced enhancement of uptake of noradrenaline in atrial strips.
    Bhagat B; Burke WJ; Dhalla NS
    Br J Pharmacol; 1981 Oct; 74(2):325-32. PubMed ID: 6274461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.